Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | Industry Therapeutic Update from Biogen: Patient-centered AD clinical care: an evolving journey

Monday 04/04/22
07:00 PM - 10:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
General Neurology
Following an initial discussion of the practical first steps of holistic, patient-centered management following a diagnosis of Alzheimer’s disease (AD) in the early stages, we will explore what matters most to patients with AD and their caregivers. With consideration to these topics, and with the help of a panel discussion, we will then discuss the implications that recent research advancements in diagnosis and monitoring may have on future clinical care. Finally, a live Q&A session will provide delegates the opportunity to ask questions. 
 
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2022 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. 
 
The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
0.00 credit

Program Materials Program Evaluations

Event Timeline
07:00 PM - 10:00 PM PDT Speaker Industry Therapeutic Update from Biogen: Patient-centered AD clinical care: an evolving journey
Faculty Disclosures
James E. Galvin, MD, MPH No disclosure on file
Kathleen A. Welsh-Bohmer No disclosure on file
Dylan P. Wint, MD Dr. Wint has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Pharmaceuticals. Dr. Wint has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Wint has received research support from National Institutes of Health (NIH). The institution of Dr. Wint has received research support from Health Resources and Services Administration (HRSA).